Status:
TERMINATED
Pharmacodynamic Effects of Anti-Vascular Endothelial Growth Factor Therapy in Patients With Advanced Malignancies
Lead Sponsor:
National University Hospital, Singapore
Conditions:
Hypertension
Proteinuria
Eligibility:
All Genders
21+ years
Brief Summary
1. To determine the effect of anti-vascular endothelial growth factor (VEGF) on endothelial function and on retinal microvasculature 2. To determine endothelial dysfunction as a marker of early respon...
Detailed Description
The well-established role of vascular endothelial growth factor (VEGF) in carcinogenesis and tumor angiogenesis has led to the development of agents that target this pathway. Anti-VEGF agents the VEGF...
Eligibility Criteria
Inclusion
- Patients who are receiving single agent anti-VEGF therapy
- Signed written informed consent.
- Patients with measurable pulmonary malignancy (primary or metastatic) as determined by RECIST will undergo assessment of pulmonary function.
- Patients with a known allergy to intravenous contrast used in fluorescein and indocyanine green angiography will be exempt from these investigations but will undergo other study assessments
Exclusion
- none
Key Trial Info
Start Date :
August 1 2007
Trial Type :
OBSERVATIONAL
End Date :
May 1 2010
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00698659
Start Date
August 1 2007
End Date
May 1 2010
Last Update
December 11 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National University Hospital
Singapore, Singapore